Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aptose Biosciences Inc.
Report date June 30, 2026 · Filed July 01, 2026
Section 16 reporting ended · disclosed 2026-07-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-06-30 transaction · row 1
1 source rowRow 1 · 2026-06-30 · Disposition to issuer · Disposed 222 · Balance 0 F1: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Inc. whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. F2: Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00. |
| Common SharesSEC Table I · non-derivative | IndirectFletcher Payne 2019 Trust | 0 |
Reported balance
After 2026-06-30 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-06-30 · Disposition to issuer · Disposed 22 · Balance 0 F1: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Inc. whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. F2: Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2034-02-05 | Direct | 0 |
Reported balance
After 2026-06-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-30 · Disposition to issuer · Disposed 55,000 · Balance 0 F1: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Inc. whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. F3: Options vest 50% on the first anniversary of the grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2033-01-19 | Direct | 0 |
Reported balance
After 2026-06-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-30 · Disposition to issuer · Disposed 200,000 · Balance 0 F1: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Inc. whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. F3: Options vest 50% on the first anniversary of the grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
| Common Stock (Option)SEC Table II · derivative / convertible security · Conversion / exercise price $0.85 · Expires 2032-06-26 | Direct | 0 |
Reported balance
After 2026-06-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-30 · Disposition to issuer · Disposed 1,000,000 · Balance 0 F1: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Inc. whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. F3: Options vest 50% on the first anniversary of the grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Inc. whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share.
F2: Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00.
F3: Options vest 50% on the first anniversary of the grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date.
GYRE THERAPEUTICS, INC.
Report date August 30, 2019 · Filed September 25, 2019
Section 16 reporting ended · disclosed 2019-09-25. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 1, 2026 20:49 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | Disposition to issuerCommon Stock (Option) · Derivative | 1,000,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0000912282-26-000895 · form4.xml · derivative · entry 5 Payne Fletcher · CIK 0001650476 · FORMER SVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000,000 shares Expires 2032-06-26 F1 · kind: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Inc. whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. F3 · derivative.exercise_date: Options vest 50% on the first anniversary of the grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:49 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0000912282-26-000895 · form4.xml · derivative · entry 4 Payne Fletcher · CIK 0001650476 · FORMER SVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 200,000 shares Expires 2033-01-19 F1 · kind: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Inc. whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. F3 · derivative.exercise_date: Options vest 50% on the first anniversary of the grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:49 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0000912282-26-000895 · form4.xml · derivative · entry 3 Payne Fletcher · CIK 0001650476 · FORMER SVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 55,000 shares Expires 2034-02-05 F1 · kind: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Inc. whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. F3 · derivative.exercise_date: Options vest 50% on the first anniversary of the grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:49 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | Disposition to issuerCommon Shares | 22 | $1.72 | $37.84 |
DisclosureSEC source: 0000912282-26-000895 · form4.xml · nonDerivative · entry 2 Payne Fletcher · CIK 0001650476 · FORMER SVP AND CFO 10b5-1 filing: No plan indicated Ownership: Indirect · Fletcher Payne 2019 Trust Disclosed balance after: 0 F1 · kind: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Inc. whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. F2 · price: Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:49 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | Disposition to issuerCommon Shares | 222 | $1.72 | $381.84 |
DisclosureSEC source: 0000912282-26-000895 · form4.xml · nonDerivative · entry 1 Payne Fletcher · CIK 0001650476 · FORMER SVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Inc. whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. F2 · price: Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 23:06 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantEmployee Stock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0000912282-24-000134 · form4.xml · derivative · entry 1 Payne Fletcher · CIK 0001650476 · Sr VP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Shares · 55,000 shares Expires 2034-02-05 F1 · derivative.exercise_date: 50% of the options vest on February 5, 2025, and the remaining options vesting as follows: 1/3 on February 5, 2026; 1/3 on February 5, 2027; and 1/3 on February 5, 2028. Read SEC document |
| January 19, 2023 Filed Jan 24, 2023 00:57 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001567619-23-001162 · doc1.xml · derivative · entry 3 Payne Fletcher · CIK 0001650476 · SR VP & Chief Fin. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Shares · 200,000 shares Expires 2033-01-19 F1 · derivative.exercise_date: Fifty percent (50%) of the options vest on January 19, 2024; the remaining fifty percent (50%) vest as follows: One-third (1/3) on January 19, 2025; one-third (1/3) on January 19, 2026; and one-third (1/3) on January 19, 2027. Read SEC document |
| January 19, 2023 Filed Jan 24, 2023 00:57 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantCommon Shares | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-001162 · doc1.xml · nonDerivative · entry 1 Payne Fletcher · CIK 0001650476 · SR VP & Chief Fin. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 22:06 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | PurchaseCommon Shares | 10,000 | $0.68 | $6,775.00 |
DisclosureSEC source: 0001567619-22-017697 · doc1.xml · nonDerivative · entry 1 Payne Fletcher · CIK 0001650476 · SR VP & Chief Fin. Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Fletcher Payne 2019 Trust Disclosed balance after: 10,000 Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 20:16 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantCommon Stock · Derivative | 1,000,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001567619-22-013453 · doc1.xml · derivative · entry 1 Payne Fletcher · CIK 0001650476 · SR VP & Chief Fin. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2032-06-26 F1 · derivative.exercise_date: The options vest as follows: 50% of the options vest on 6/27/2023; the remaining options will vest in equal annual installments on June 27, 2024, June 27, 2025, and June 27, 2026. Read SEC document |
| August 12, 2019 Filed Aug 12, 2019 20:22 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 1,180 | $6.51 | $7,681.80 |
DisclosureSEC source: 0001209191-19-045506 · doc4.xml · nonDerivative · entry 1 Payne Fletcher · CIK 0001650476 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,744 F1 · shares: Shares purchased under the Catalyst Biosciences, Inc. 2018 Employee Stock Purchase Plan ("ESPP") on August 12, 2019. Read SEC document |
| February 11, 2019 Filed Feb 14, 2019 00:19 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 1,002 | $7.04 | $7,054.08 |
DisclosureSEC source: 0001209191-19-009885 · doc4.xml · nonDerivative · entry 1 Payne Fletcher · CIK 0001650476 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,731 F1 · shares: Shares purchased under the Catalyst Biosciences, Inc. 2018 Employee Stock Purchase Plan ("ESPP") on February 11, 2019. Read SEC document |
| February 04, 2019 Filed Feb 4, 2019 21:52 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,503 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0001209191-19-006858 · doc4.xml · derivative · entry 2 Payne Fletcher · CIK 0001650476 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,497 Underlying: Common Stock · 1,503 shares Expires 2027-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Option vests monthly over a period of four years commencing June 15, 2017. Read SEC document |
| February 04, 2019 Filed Feb 4, 2019 21:52 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Exercise / conversionCommon Stock | 1,503 | $4.63 | $6,958.89 |
DisclosureSEC source: 0001209191-19-006858 · doc4.xml · nonDerivative · entry 1 Payne Fletcher · CIK 0001650476 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,230 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2019 Filed Jan 28, 2019 23:56 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 38,000 | $0.00 Strike: $7.97 | $0.00 |
DisclosureSEC source: 0001209191-19-005667 · doc4.xml · derivative · entry 1 Payne Fletcher · CIK 0001650476 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2029-01-24 F1 · derivative.exercise_date: Award vests over a four (4) year period on each monthly anniversary commencing January 24, 2019. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 21:48 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $9.68 | $0.00 |
DisclosureSEC source: 0001209191-18-044790 · doc4.xml · derivative · entry 1 Payne Fletcher · CIK 0001650476 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-07-30 F1 · derivative.exercise_date: Award vests monthly over four (4) years starting June 13, 2018. Read SEC document |
| March 26, 2018 Filed Mar 28, 2018 20:11 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Exercise / conversionStock Option (Right to Buy) · Derivative | 59 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0001209191-18-021896 · doc4.xml · derivative · entry 3 Payne Fletcher · CIK 0001650476 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,941 Underlying: Common Stock · 59 shares Expires 2027-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Option vests monthly over a period of four years commencing June 15, 2017. Read SEC document |
| March 26, 2018 Filed Mar 28, 2018 20:11 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Exercise / conversionCommon Stock | 59 | $4.63 | $273.17 |
DisclosureSEC source: 0001209191-18-021896 · doc4.xml · nonDerivative · entry 1 Payne Fletcher · CIK 0001650476 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 12, 2018 Filed Jan 16, 2018 20:43 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $15.13 | $0.00 |
DisclosureSEC source: 0000899243-18-001063 · doc4.xml · derivative · entry 1 Payne Fletcher · CIK 0001650476 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2028-01-12 F1 · derivative.exercise_date: The Option vests monthly over a period of four years commencing January 12, 2018. Read SEC document |
| July 11, 2017 Filed Jul 12, 2017 20:47 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0001209191-17-044901 · doc4.xml · derivative · entry 1 Payne Fletcher · CIK 0001650476 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-07-11 F1 · derivative.exercise_date: The Option vests monthly over a period of four years commencing June 15, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.